Heteroplasmic pathogenic m. 12315G >A variant in MT‐TL2 presenting with MELAS syndrome and depletion of nitric oxide donors
American Journal of Medical Genetics Part A · 2024
DOI: 10.1002/ajmg.a.63461 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2024. Verfasst von Matthew T Snyder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Acidosis, Lactic, MELAS Syndrome, Mitochondrial Encephalomyopathies, Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
The MT‐TL2 m.12315G>A pathogenic variant has previously been reported in five individuals with mild clinical phenotypes. Herein we report the case of a 5‐year‐old child with heteroplasmy for this variant who developed neurological regression and stroke‐like episodes similar to those observed in mitochondrial encephalopathy, lactic acidosis, and stroke‐like episodes (MELAS). Biochemical evaluation revealed depletion of arginine on plasma amino acid analysis and low z ‐scores for citrulline on untargeted plasma metabolomics analysis. These findings suggested that decreased availability of nitric oxide may have contributed to the stroke‐like episodes. The use of intravenous arginine during stroke‐like episodes and daily enteral L‐citrulline supplementation normalized her biochemical values of arginine and citrulline. Untargeted plasma metabolomics showed the absence of nicotinamide and 1‐methylnicotinamide, and plasma total glutathione levels were low; thus, nicotinamide riboside and N‐acetylcysteine therapies were initiated. This report expands the phenotype associated with the rare mitochondrial variant MT‐TL2 m.12315G>A to include neurological regression and a MELAS‐like phenotype. Individuals with this variant should undergo in‐depth biochemical analysis to include untargeted plasma metabolomics, plasma amino acids, and glutathione levels to help guide a targeted approach to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
- Texas Children's Hospital, Houston, Texas, USA.
- Metabolic Diseases Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
- Department of Radiology, Baylor College of Medicine, Houston, Texas, USA.
- Department of Pediatrics, Division of Pediatric Neurology and Developmental Neuroscience, Baylor College of Medicine, Houston, Texas, USA.
- Joint BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, Hong Kong SAR, China.
ORCID-Profile: Joshua Manor, Fernando Scaglia
Zitieren
APA
Snyder, M. T., Manor, J., Gijavanekar, C., Mizerik, E., Kralik, S. F., Elsea, S. H., Machol, K., Emrick, L., & Scaglia, F. (2024). Heteroplasmic pathogenic m. 12315G >A variant in MT‐TL2 presenting with MELAS syndrome and depletion of nitric oxide donors. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63461
Vancouver
Snyder MT, Manor J, Gijavanekar C, Mizerik E, Kralik SF, Elsea SH, et al. Heteroplasmic pathogenic m. 12315G >A variant in MT‐TL2 presenting with MELAS syndrome and depletion of nitric oxide donors. American Journal of Medical Genetics Part A. 2024. doi:10.1002/ajmg.a.63461
BibTeX
@article{Snyder2024,
author = {Snyder, Matthew T and Manor, Joshua and Gijavanekar, Charul and Mizerik, Elizabeth and Kralik, Stephen F and Elsea, Sarah H and Machol, Keren and Emrick, Lisa and Scaglia, Fernando},
title = {Heteroplasmic pathogenic m. 12315G >A variant in MT‐TL2 presenting with MELAS syndrome and depletion of nitric oxide donors},
journal = {American Journal of Medical Genetics Part A},
year = {2024},
doi = {10.1002/ajmg.a.63461}
}
EUVIMED